Invitris was founded with the mission to revolutionize drug creation through efficient and cost-effective synthetic biology. The company’s core vision is to simplify the development of novel biological drugs using its patent-pending technology platform, which transforms DNA into synthetic proteins. This platform significantly enhances the efficiency and reduces the cost of material for drug creation. Invitris specializes in producing synthetic bacteriophages to combat antibiotic-resistant infections, a critical health threat projected to surpass cancer in mortality rates. Their market focus is primarily on human therapeutics, partnering with other companies to create and manufacture new protein-based products.

Notable individuals affiliated with Invitris include experts in synthetic biology and biotechnology, though specific names are not provided. The company has garnered attention from prestigious publications like Science magazine, highlighting its innovative approach. Key achievements include the development of a universal platform technology that enables high-yield, high-purity synthetic protein generation. Invitris’s impact lies in its potential to transform the pharmaceutical industry by making drug development faster, cheaper, and more effective, particularly in addressing antibiotic resistance.